- Pharmaceutical firm Novo Nordisk is expected to surpass its trading forecasts, driven by the high demand for its new Wegovy weight loss pill.
- Shares in the Copenhagen-based company rose following the announcement, as Wegovy's January launch directly challenged rival Eli Lilly's Mounjaro.
- Wegovy has achieved the strongest debut for any obesity drug in the US market, with over two million prescriptions issued and weekly figures exceeding 200,000.
- The pill generated 2.26 billion Danish krone (£261 million) in sales during the quarter ending 31 March, surpassing analyst predictions.
- Despite a dip in adjusted net sales and operating profit for the quarter, Novo Nordisk has raised its 2026 guidance for both adjusted sales and operating profit, citing Wegovy's strong performance.
IN FULL
Novo Nordisk shares soar as sales of Wegovy weight loss pill smash forecasts